Dashboard
Manage Tickers

PSTVPLUS THERAPEUTICS, INC.

Nasdaq plustherapeutics.com


$ 1.37 $ -0.04 (-2.86 %)    

Friday, 16-Aug-2024 15:55:26 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 475.66 $ 0.00 (0 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.89 $ 0.00 (0 %)
TLT $ 97.94 $ 0.00 (0 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 1.36
$ 1.36 x 181
-- x --
-- - --
$ 0.97 - $ 3.21
88,263
na
14.61M
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 10-31-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 04-20-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 10-20-2022 09-30-2022 10-Q
9 07-21-2022 06-30-2022 10-Q
10 04-21-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 10-21-2021 09-30-2021 10-Q
13 07-22-2021 06-30-2021 10-Q
14 04-22-2021 03-31-2021 10-Q
15 02-22-2021 12-31-2020 10-K
16 10-22-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-30-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-15-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-29-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-11-2018 03-31-2018 10-Q
27 03-09-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 05-12-2017 03-31-2017 10-Q
31 03-24-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-11-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-plus-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Plus...
08/16/2024 12:19:39

HC Wainwright & Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $8 price target.

plus-therapeutics-q2-2024-adj-eps-071-misses-053-estimate
Plus Therapeutics Q2 2024 Adj EPS $(0.71) ...
08/14/2024 20:45:25

Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $...

plus-therapeutics-q2-sales-128m-miss-168m-estimate
Plus Therapeutics Q2 Sales $1.28M Miss $1....
08/14/2024 20:15:45

Plus Therapeutics (NASDAQ:PSTV) reported quarterly sales of $1.28 million which missed the analyst consensus estimate of $1.68 ...

plus-therapeutics-says-cnside-leptomeningeal-metastases-forsee-trial-met-key-primary-and-secondary-endpoints
Plus Therapeutics Says CNSide Leptomeninge...
08/13/2024 11:32:47

The data were presented in a podium presentation at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Onco...

plus-therapeutics-presented-data-in-podium-presentation-updating-the-progress-of-its-respect-lm-trial-of-rhenium-obisbemeda-in-leptomeningeal-disease-at-the-2024-society-for-neurooncologyamerican-society-for-clinical-oncology-cns-metastases-conference
Plus Therapeutics Presented Data In Podium...
08/12/2024 11:32:16

plus-therapeutics-says-greg-fuller-joins-company-as-vice-president-of-medical-affairs-and-medical-director-reports-33m-advance-payment-from-cprit
PLUS THERAPEUTICS Says Greg Fuller Joins C...
06/07/2024 11:40:53

The Company received notice of an advance payment of $3.3 million from CPRIT, part of the $17.6 million award granted in Septem...

plus-therapeutics-q1-2024-gaap-eps-075-beats-109-estimate-sales-1677m-miss-1688m-estimate
Plus Therapeutics Q1 2024 GAAP EPS $(0.75)...
05/15/2024 20:34:53

Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1...

plus-therapeutics-has-acquired-assets-for-the-synergistic-leptomeningeal-metastases-diagnostic-platform-financial-terms-not-disclosed-topline-clinical-trial-data-on-the-foresee-trial-met-its-primary-endpoint-of-clinical-utility
Plus Therapeutics Has Acquired Assets For ...
05/09/2024 15:36:06

CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rh...

plus-therapeutics-shares-are-trading-higher-after-the-company-announced-a-private-placement-financing-of-up-to-18-million
Plus Therapeutics shares are trading highe...
05/06/2024 11:36:29

plus-therapeutics-announced-private-placement-of-up-to-approximately-18m-in-gross-proceeds-including-initial-upfront-funding-of-approximately-65m-and-up-to-an-additional-approximately-115m-upon-cash-exercise-of-accompanying-warrants-at-the-election
Plus Therapeutics Announced Private Placem...
05/06/2024 11:33:54

micro-cap-brain-cancer-focused-plus-therapeutics-poised-to-receive-3m-from-us-department-of-defense
Micro-Cap Brain Cancer Focused Plus Therap...
04/22/2024 11:00:19

Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.

plus-therapeutics-says-plus-now-has-23-million-in-active-awards-support-for-the-companys-targeted-radiotherapeutic-pipeline
Plus Therapeutics Says 'Plus now has $23 m...
04/22/2024 11:00:15

plus-therapeutics-receives-3m-award-recommendation-from-the-us-department-of-defense
Plus Therapeutics Receives $3M Award Recom...
04/22/2024 11:00:08

plus-therapeutics-announces-validation--clinical-implementation-of-csf-01-leptomeningeal-cancer-cell-diagnostic
Plus Therapeutics Announces Validation & C...
03/25/2024 12:09:31

Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma an...

plus-therapeutics-has-completed-dosing-in-cohort-5-of-respect-lm-phase-1-dose-escalation-trial-of-rhenium-186re-obisbemeda-for-leptomeningeal-metastases-from-solid-tumors-company-expects-moving-into-cohort-6-in-q2-2024-following-standard-safety-review
Plus Therapeutics Has Completed Dosing In ...
03/11/2024 11:21:12

recap-plus-therapeutics-q4-earnings
Recap: Plus Therapeutics Q4 Earnings
03/05/2024 21:35:11

plus-therapeutics-q4-eps-070-beats-107-estimate-sales-131m-beat-106m-estimate
Plus Therapeutics Q4 EPS $(0.70) Beats $(1...
03/05/2024 21:30:53

Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1...

earnings-scheduled-for-march-5-2024
Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

plus-therapeutics-earnings-preview
Plus Therapeutics Earnings Preview
03/04/2024 18:03:14

plus-therapeutics-says-the-award-payment-of-33m-together-with-its-cash-on-hand-provides-sufficient-runway-to-fund-operations-to-2h-2025
Plus Therapeutics Says The Award Payment O...
12/18/2023 12:21:11

The Company forecasts an additional $6.9 million in grant revenue during the 2024 calendar year.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION